COMP <GO>
INFU vs TMCI // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
InfuSystems Holdings Inc. (NYSE) VS. Treace Medical Concepts Inc. (NASDAQ) • 15-METRIC TALLY: INFU 8
— TMCI 2
■ METRIC PARITY
LAST: $13.84 (-1.63%) • MKT CAP: $280.2M
options-implied-move
—
LAST: $4.27 (-3.61%) • MKT CAP: $288.1M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. TMCI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | TMCI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.00% | 79.80% | -23.80 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | -32.40% | +45.20 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | -8.96% | +17.25 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | -25.50% | +33.80 | INFU | /operating-margins <GO> |
| Net Profit Margin | 4.60% | -27.70% | +32.30 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 1.60% | +4.80 | INFU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 0.90 | +4.26 | INFU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.3 | 50.3 | +6.00 | INFU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $280.2M | $288.1M | -$7.9M | TMCI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | TMCI REV | INFU GROSS % | TMCI GROSS % | INFU FCF | TMCI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $212.7M | 56.0% | 79.8% | $23.8M | -$29.5M |
| FY 2024 | $134.9M | $209.4M | 52.2% | 80.4% | $19.4M | -$48.8M |
| FY 2023 | $125.8M | $187.1M | — | — | $11.2M | -$34.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
TMCI // BETA —